DECR2 (2.4-Dienoyl-CoA Reductase 2) is a mitochondrial enzyme involved in the β-oxidation of polyunsaturated fatty acids (PUFAs). It catalyzes the reduction of 2.4-dienoyl-CoA to 3-enoyl-CoA, a critical step in metabolizing unsaturated fatty acids with double bonds at even-numbered positions. DECR2 is essential for maintaining energy homeostasis, particularly in tissues with high fatty acid oxidation demands, such as the heart and liver. Dysregulation of DECR2 has been linked to metabolic disorders, neurodegenerative diseases, and cancer, highlighting its role in cellular redox balance and lipid metabolism.
DECR2 antibodies are immunological tools developed to detect and quantify DECR2 protein expression in various experimental models. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study DECR2's tissue distribution, subcellular localization, and expression changes under pathological conditions. Some antibodies target specific epitopes or post-translational modifications, enabling research into DECR2's functional regulation. Commercial DECR2 antibodies are often validated for specificity using knockout controls or siRNA-mediated silencing. Recent studies employ DECR2 antibodies to explore its involvement in oxidative stress, inflammation, and mitochondrial dysfunction, positioning it as a potential therapeutic target. However, antibody performance may vary depending on species reactivity, fixation methods, or sample preparation, necessitating careful optimization.